These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2810387)

  • 1. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma.
    Griffith KD; Read EJ; Carrasquillo JA; Carter CS; Yang JC; Fisher B; Aebersold P; Packard BS; Yu MY; Rosenberg SA
    J Natl Cancer Inst; 1989 Nov; 81(22):1709-17. PubMed ID: 2810387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
    Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC
    Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.
    Fisher B; Packard BS; Read EJ; Carrasquillo JA; Carter CS; Topalian SL; Yang JC; Yolles P; Larson SM; Rosenberg SA
    J Clin Oncol; 1989 Feb; 7(2):250-61. PubMed ID: 2644399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer.
    Dillman RO; Hurwitz SR; Schiltz PM; Barth NM; Beutel LD; Nayak SK; O'Connor AA
    Cancer Biother Radiopharm; 1997 Apr; 12(2):65-71. PubMed ID: 10851449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.
    Economou JS; Belldegrun AS; Glaspy J; Toloza EM; Figlin R; Hobbs J; Meldon N; Kaboo R; Tso CL; Miller A; Lau R; McBride W; Moen RC
    J Clin Invest; 1996 Jan; 97(2):515-21. PubMed ID: 8567975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes.
    Cole DJ; Taubenberger JK; Pockaj BA; Yannelli JR; Carter C; Carrasquillo J; Leitman S; Steinberg SM; Rosenberg SA; Yang YC
    Cancer Immunol Immunother; 1994 May; 38(5):299-303. PubMed ID: 8162611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial.
    Dillman RO; Oldham RK; Barth NM; Cohen RJ; Minor DR; Birch R; Yannelli JR; Maleckar JR; Sferruzza A; Arnold J
    Cancer; 1991 Jul; 68(1):1-8. PubMed ID: 2049729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
    Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
    J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo distribution of radio-labeled tumor infiltrating lymphocytes in cancer patients.
    Chin Y; Janssens J; Bleus J; Zhang J; Raus J
    In Vivo; 1993; 7(1):27-30. PubMed ID: 8504205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
    Schwartzentruber DJ; Hom SS; Dadmarz R; White DE; Yannelli JR; Steinberg SM; Rosenberg SA; Topalian SL
    J Clin Oncol; 1994 Jul; 12(7):1475-83. PubMed ID: 8021739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct cytotoxicity against neuroblastoma cells of peripheral blood and tumor-infiltrating lymphocytes from patients with neuroblastoma.
    Kataoka Y; Matsumura T; Yamamoto S; Sugimoto T; Sawada T
    Cancer Lett; 1993 Sep; 73(1):11-21. PubMed ID: 8402593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
    Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
    Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
    Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
    Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
    Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: a case study.
    Aebersold P; Kasid A; Rosenberg SA
    Hum Gene Ther; 1990; 1(4):373-84. PubMed ID: 1964094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging pattern of previously in vitro sensitized and interleukin-2 expanded autologous lymphocytes in human cancer.
    Mukherji B; Arnbjarnarson O; Spitznagle LA; Kalish RI; Hoffman J; Ergin MT; Spencer RP
    Int J Rad Appl Instrum B; 1988; 15(4):419-27. PubMed ID: 3267147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.